WIPO Re:Search puts a range of supporting services related to capacity building, knowledge transfer, and access to innovation information, at the disposal of its members and developing countries.
Access to health innovation information
WIPO provides general and detailed information about all aspects of the intellectual property system, including:
WIPO provides training courses that help developing country R&D institutions obtain maximum benefit from their intellectual property:
- Practical aspects of IP management in developing country R&D institutions.
- Technology transfer and related agreements.
- Setting up technology management offices in R&D institutions.
Articles and reports
A number of articles and reports touch on matters related to the work of WIPO Re:Search. We've put together a selection of the best for you to browse.
- 2016 - BVGH Partnership Hub Report - Catalyzing Partnerships for Global Health
- Global Challenges Report: Strategic Review of WIPO Re:Search, including Response from the WIPO Secretariat
- Global Challenges Brief: The changing landscape of medical innovation: How have business models responded?
- Global Challenges Report: Patent Information, Freedom to Operate and "Global Access": A Case Study of Dengue Vaccines Under Development
- WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-related Patents and Patent Applications
- WIPO Re:Search Helps Take the “Neglected” out of Tropical Diseases
- WIPO Magazine: Catalyzing research into neglected tropical diseases
- WIPO Magazine: WIPO Re:Search - IP at Work for Social Benefit
- WIPO Re:Search: Accelerating R&D through cross-sector partnerships, International Journal for Parasitology
R&D knowledge transfer
WIPO Re:Search helps developing countries increase their scientific and research capacity through its program of research sabbaticals, generously supported by funds-in-trust from the Government of Australia.
These sabbaticals allow developing country research institutions to learn from world-class laboratories.
Prof. Wellington Oyibo of the University of Lagos (Nigeria) spent three months at Novartis' laboratories in Basel (Switzerland).